学術論文|株式会社アミンファーマ研究所

[2014-1] Mizoi et al., Clin. Chim. Acta 430, 150-155 (2014)

BACKGROUND: We found previously that the amyloid b40/42 (Ab40/42) ratio and the level of protein-conjugated acrolein (PC-Acro) in plasma were increased in mild cognitive impairment (MCI) and Alzheimer’s disease (AD) subjects. We determined whether MCI and AD subjects can be differentiated based on the levels of Ab40, Ab42, and PC-Acro in cerebrospinal fluid (CSF).

METHODS: Ab40, Ab42, PC-Acro, Tau and phosphorylated Tau in CSF were measured by ELISA.

RESULTS: Median values of Ab40, Ab40/PC-Acro and Ab40/42 in CSF were significantly lower in 54 AD subjects than those in 40 MCI subjects. Severity of VOI (volume of interest) atrophy was most intensely correlated with the decrease in Ab40/PC-Acro and then that in Ab40 and Ab42/PC-Acro. MMSE was most intensely correlated with the decrease in Ab42 and Ab40, and then that in Ab42/PC-Acro and Ab40/PC-Acro.

CONCLUSION: A decrease in Ab40/PC-Acro in CSF is well correlated with brain damage, and a decrease in Ab42 and Ab40 is well correlated with cognitive ability. Measurement of PC-Acro together with Ab40 and Ab42 provides a more precise evaluation of severity of AD subjects.

学術論文|株式会社アミンファーマ研究所